The following is a summary of “Effect of 3-Dimensional Imaging Device on Polyp and Adenoma Detection During Colonoscopy: A Randomized Controlled Trial,” published in the October 2023 issue of Gastroenterology by Sun, et al.
For a study, researchers sought to investigate the influence of a 3-dimensional (3D) imaging device on detecting polyps and adenomas during colonoscopies.
In a single-blind, randomized controlled trial, individuals aged 18 to 70 undergoing diagnostic or screening colonoscopies were consecutively enrolled from August 2019 to May 2022. Using computer-generated random numbers, participants were randomly allocated to either 2-dimensional (2D-3D) or 3D-2D colonoscopy at a 1:1 ratio. The primary outcome metrics included the polyp detection rate (PDR) and adenoma detection rate (ADR), defined as the proportion of participants in at least one polyp or adenoma identified during the colonoscopy. The primary analysis adhered to the intention-to-treat principle.
From the initial 1,196 participants, 571 were placed in the 2D-3D group and 583 in the 3D-2D group, following exclusions for participants meeting specific criteria. During phase 1, the PDR was 39.6% in the 2D group and 40.5% in the 3D group, with no statistically significant difference (odds ratio [OR] = 0.96, 95% CI: 0.76–1.22, P = 0.801). However, during phase 2, the 3D group exhibited a significantly higher PDR of 27.7% compared to the 2D group’s 19.9%, signifying a 1.54-fold increase (1.17–2.02, P = 0.002). Similarly, during phase 1, the ADR was 24.7% in the 2D group and 23.8% in the 3D group, with no significant disparity (OR = 1.05, 0.80–1.37, P = 0.788). Nevertheless, in phase 2, the 3D group displayed a noticeably higher ADR of 13.8% compared to the 2D group’s 9.9%, denoting a 1.45-fold increase (1.01–2.08, P = 0.041). Subgroup analysis substantiated the significantly greater PDR and ADR within the 3D group during phase 2, especially among mid-level and junior endoscopists.
The 3D imaging device enhances the overall PDR and ADR during colonoscopies, particularly benefiting mid-level and junior endoscopists.